000048632 000__ 01351nam\a2200397\i\4500
000048632 001__ 48632
000048632 003__ SzGeWIPO
000048632 005__ 20240708150412.0
000048632 006__ m    eo  d        
000048632 007__ cr bn |||m|||a
000048632 008__ 231029s2023\\\\enk\\\\\o\\\\\000\0\eng\d
000048632 0247_ $$a10.1093/grurint/ikad044$$2doi
000048632 035__ $$a(OCoLC)1411269714
000048632 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000048632 041__ $$aeng
000048632 24500 $$aCriteria to Assess Whether a Medicine Should Be Entered in the List of Reimbursable Treatments.
000048632 264_1 $$a[Oxford, England] :$$bOxford University Press (OUP),$$c2023
000048632 300__ $$a1 online resource (pages 596–598)
000048632 336__ $$atext$$2rdacontent
000048632 337__ $$acomputer$$2rdamedia
000048632 338__ $$aonline resource$$bcr$$2rdacarrier
000048632 4901_ $$aGRUR International,$$x2632-8550 ;$$v72, 5, 2023
000048632 542__ $$fhttps://academic.oup.com/grurint/article/72/3/231/6998505
000048632 588__ $$aCrossref
000048632 590__ $$aPublished online: 04-May-23
000048632 650_0 $$aPatents$$xLaw and legislation.
000048632 650_0 $$aPharmaceuticals.
000048632 650_0 $$aPatent medication.
000048632 650_0 $$aPharmaceutical policy.
000048632 650_0 $$aPatents.
000048632 650_0 $$aCOVID-19 (Disease)
000048632 7731_ $$tGRUR International$$wGRUR
000048632 830_0 $$aGRUR International,$$x2632-8550 ;$$v72, 5, 2023.
000048632 85641 $$uhttps://doi.org/10.1093/grurint/ikad044$$yonline version
000048632 904__ $$aJournal article
000048632 980__ $$aGRUR